Almac Diagnostic Services receives CIR (French Research Tax Credit) Accreditation

July 31, 2019

French research companies can utilise Almac laboratory capabilities to avail of tax break on R&D activities.

Almac Diagnostic Services receives CIR (French Research Tax Credit) Accreditation 700x400Craigavon, N.I., 31st July 2019Almac Diagnostic Services, a global stratified medicine company and member of the Almac Group, today announced it has received CIR (French Research Tax Credit) Accreditation for a three-year period from the French Ministry of Higher Education, Research & Innovation.

The French R&D tax credit initiative (“Crédit d’Impôt Recherche”, or CIR) gives eligible research-based French companies, which are subject to corporate tax in France, the ability to claim tax relief of up to 30% on costs incurred in R&D activities.

Michael Sloan, Global VP of Commercial Operations at Almac Diagnostic Services, commented: “We are pleased to receive this accreditation as it allows both our existing, and potential future, French based clients to benefit from significant tax relief on their R&D expenditure when conducting biomarker discovery work with our diagnostic laboratory. This is a significant saving for any SME undertaking this vital research.”

About CIR
The Research Tax Credit (CIR) is a central tool of the French Government provided as a tax benefit allowing the growth of businesses competitiveness by favouring research and development (R&D) and innovative activities. It is particularly adapted to the needs of small and medium-sized enterprises.

More information on the Almac accreditation and CIR can be found here.


About Almac Diagnostic Services

Almac Diagnostic Services is a global stratified medicine company specialising in biomarker driven clinical trials. The company is focused on the discovery, development and commercialisation of diagnostic and companion diagnostic tests.

We partner with biopharma companies to provide solutions ranging from biomarker discovery to CDx development including regulatory submissions and commercialisation. We also facilitate biomarker clinical trial management and clinical test delivery from our CLIA-accredited labs.

The tests developed at Almac Diagnostic Services have a wide range of applications including patient selection, and are utilised in phase I to phase III registrational clinical trials.

For more information visit:

About Almac Group
A unique culture delivering exceptional solutions

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has grown organically over the past five decades now employing over 5600 highly skilled personnel across 18 facilities including Europe, the US and Asia.

We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients.

To keep up to date with our latest news, follow us on Twitter and LinkedIn or visit


Back to news